Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders

Blood Cancer Journal

Volumn 2, Issue 9, 2012, Pages

  Perrot, A ^a,b,c   Pionneau, C ^d,e   Azar, N ^f   Baillou, C ^e,g   Lemoine, F M ^e,g   Leblond, V ^e,f   Merle Beral H ^e,f   Bene M C ^c   Herbrecht, R ^h   Bahram, S ^a,b   Vallat, L ^a,b  

^a Centre de Recherche D'Immunologie et D'Hematologie   (France)

^b Nouvel Ho Pital Civil   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CNRS   (France)

^h UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; KU ANTIGEN;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DNA END JOINING REPAIR; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LYMPHOPROLIFERATIVE DISEASE; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WALDENSTROEM MACROGLOBULINEMIA; WESTERN BLOTTING;

EID: 84871092807     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.35     Document Type: Article

References (50)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564-1577.
2. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
3. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994; 83: 3647-3653.
4. Kriangkum J, Taylor BJ, Reiman T, Belch AR, Pilarski LM. Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor? Clin Lymphoma 2005; 5: 217-219.
5. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104: 2134-2142.
6. Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100: 1505-1507.
7. Kriangkum J, Taylor BJ, Strachan E, Mant MJ, Reiman T, Belch AR et al. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. Blood 2006; 107: 2920-2927.
8. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-563.
9. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 2007; 449: 478-482.
10. Nick McElhinny SA, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol 2000; 20: 2996-3003.
11. Mari PO, Florea BI, Persengiev SP, Verkaik NS, Bruggenwirth HT, Modesti M et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proc Natl Acad Sci USA 2006; 103: 18597-18602.
12. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108: 2755-2763.
13. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
14. Mitsiades CS, Mitsiades N, Treon SP, Anderson KC. Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol 2003; 30: 156-160.
15. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007; 67: 3777-3784.
16. Perrot A, Pionneau C, Nadaud S, Davi F, Leblond V, Jacob F et al. A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood 2011; 118: e1-e15.
17. Van den Bergh G, Arckens L. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 2004; 15: 38-43.
18. Margalit O, Somech R, Amariglio N, Rechavi G. Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. Blood Rev 2005; 19: 223-234.
19. Seto M. Genomic profiles in B cell lymphoma. Int J Hematol 2010; 92: 238-245.
20. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
21. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15: 471-486.
22. Cheng NH, Zhang W, Chen WQ, Jin J, Cui X, Butte NF et al. A mammalian monothiol glutaredoxin, Grx3, is critical for cell cycle progression during embryogenesis. FEBS J 2011; 278: 2525-2539.
23. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95: 3214-3218.
24. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003; 424: 561-565.
25. Kim SY, Chun E, Lee KY. Phospholipase A(2) of peroxiredoxin 6 has a critical role in tumor necrosis factor-induced apoptosis. Cell Death Differ 2011; 18: 1573-1583.
26. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996; 56: 4841-4845.
27. Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S et al. Inhibition of apoptosis by the actin-regulatory protein gelsolin. EMBO J 1997; 16: 4650-4656.
28. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 2006; 6: 1681-1694.
29. Enrich C, Rentero C, de Muga SV, Reverter M, Mulay V, Wood P et al. Annexin A6-Linking Ca(2) signaling with cholesterol transport. Biochem Biophys Acta 2011; 1813: 935-947.
30. Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981; 68: 611-620.
31. Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet 1994; 65: 221-227.
32. Blier PR, Griffith AJ, Craft J, Hardin JA. Binding of Ku protein to DNA. Measurement of affinity for ends and demonstration of binding to nicks. J Biol Chem 1993; 268: 7594-7601.
33. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993; 72: 131-142.
34. Ouyang H, Nussenzweig A, Kurimasa A, Soares VC, Li X, Cordon-Cardo C et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med 1997; 186: 921-929.
35. Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot J, Mizuta R et al. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 1994; 265: 1442-1445.
36. Zhu C, Bogue MA, Lim DS, Hasty P, Roth DB. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. Cell 1996; 86: 379-389.
37. Gu Y, Jin S, Gao Y, Weaver DT, Alt FW. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci USA 1997; 94: 8076-8081.
38. Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA et al. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci USA 2000; 97: 6630-6633.
39. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000; 404: 510-514.
40. Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 1998; 92: 2213-2219.
41. Riballo E, Critchlow SE, Teo SH, Doherty AJ, Priestley A, Broughton B et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999; 9: 699-702.
42. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262.
43. Moshous D, Pannetier C, Chasseval Rd R, Deist Fl F, Cavazzana-Calvo M, Romana S et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 2003; 111: 381-387.
44. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 2002; 39: 900-905.
45. Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, Severson RK et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 2006; 108: 3161-3167.
46. Chen TY, Chen JS, Su WC, Wu MS, Tsao CJ. Expression of DNA repair gene Ku80 in lymphoid neoplasm. Eur J Haematol 2005; 74: 481-488.
47. Holgersson A, Erdal H, Nilsson A, Lewensohn R, Kanter L. Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies. Exp Mol Pathol 2004; 77: 1-6.
48. Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol 2010; 149: 258-262.
49. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM et al. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. J Hematol Oncol 2010; 3: 38.
50. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62.